Navigation Links
Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
Date:7/23/2014

port plays a critical role in achieving our goals."

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc., a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has successfully completed a clinical trial for this treatment in collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. Lightlake also has successfully completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: http://www.lightlaketherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
2. Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
3. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
4. Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
5. MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics
6. Echo Therapeutics to Present at the Noble Financial Capital Markets Tenth Annual Equity Conference
7. Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
8. Echo Therapeutics Hires Product Development Management Executive
9. Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress
10. Halozyme Therapeutics Provides an Update on Anticipated Milestones for 2014 at the 32nd Annual J. P. Morgan Healthcare Conference
11. Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Inc. (NASDAQ: VRML ), a bio-analytical solutions company ... the 27 th Annual ROTH Conference, which is being ... from March 8 to March 11. ... will be presenting on Monday, March 9 at 12:00 noon ... the company,s Vice President of Finance and Chief Accounting Officer. ...
(Date:3/3/2015)... Fla. , March 3, 2015 ... pleased to announce the hiring of Brian ... to lead business development efforts and build relationships ... of experience in software development, sales, and sales ... enterprise software applications. iTraycer is a comprehensive inventory ...
(Date:3/3/2015)... March 3, 2015  Cumberland Pharmaceuticals Inc. (NASDAQ: ... on hospital acute care and gastroenterology, today announced ... developments include top-line results from the Company,s Hepatoren ... Drug Application (sNDA) with pediatric data for Caldolor ... Phase II clinical trial. "The sNDA ...
Breaking Medicine Technology:Vermillion To Present at 27th Annual ROTH Conference on March 9 2Medical Tracking Solutions, Inc. Hires New SVP, Sales 2Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 2Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 3Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 4Cumberland Pharmaceuticals Reports Clinical And Regulatory Milestones 5
... The Global Genes Project ( www.globalgenesproject.org ), ... awareness about the prevalence of rare diseases worldwide, ... The 7,000 Bracelets for Hope™ campaign is designed ... chronic, life-threatening and fatal rare diseases and disorders ...
... SEATTLE, Nov. 1, 2010 Cell Therapeutics, Inc. ... it has submitted a Marketing Authorization Application ("MAA") ... (pixantrone dimaleate) as monotherapy for the treatment of ... non-Hodgkin,s lymphoma ("NHL"). The application submission follows a ...
Cached Medicine Technology:7,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 27,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri® 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri® 3
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... 03, 2015 US Air Purifiers LLC ... purification systems, is pleased to announce that all Rabbit brand ... interruption related to the west coast port strikes. This news ... the corner. , The port strikes, which ... slow fourth quarter economic growth by as much as 1%, ...
(Date:3/3/2015)... Daylight Savings Time may lead to your kids to ... parents. , Parents and their children may feel a bit ... set their clocks forward one hour for Daylight Savings Time. ... hour earlier -- you will have already lost one hour ... “sleep hygiene” for their kids and teens this week, says ...
(Date:3/3/2015)... Rhinebeck, NY (PRWEB) March 03, 2015 Topical ... held as a webinar streamed live on Tuesday, March 10th, ... workshops will be archived and accessible 24/7. ... the public. The topic for the March 10th workshop is ... timely discussion, considering that the U.S. represents 5% of the ...
(Date:3/3/2015)... Today is International Ear Care Day, ... occasion to applaud and promote the launch of Make ... Organization (WHO) for stemming the threat of noise-induced hearing ... people to practice safe listening when they recreate, be ... sporting events, or engaging in other forms of entertainment. ...
Breaking Medicine News(10 mins):Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 2Health News:Rabbit Air Purifiers Back In Stock at US Air Purifiers LLC 3Health News:Don’t Let Daylight Savings Disrupt Your Child’s Sleep 2Health News:Topical BioMedics Hosts March Pain Management Webinar 2Health News:Topical BioMedics Hosts March Pain Management Webinar 3Health News:Topical BioMedics Hosts March Pain Management Webinar 4Health News:Topical BioMedics Hosts March Pain Management Webinar 5Health News:ASHA Applauds Launch of New WHO Campaign 2
... epidemic proportions in Gujarat according to the government there ... any part of flood-ravaged Surat.// ,Quoting the ... State Health Secretary Amarjit Singh, Delhi, said that all ... rodent samples for plague as well as for Hantavirus ...
... has ordered administrations of all 30 districts to collect Pepsi ... ,The officials were Thursday asked to send the ... department official. ,These would then be sent to ... not have testing facilities to confirm the presence of pesticides. ...
... the time that kids spend in exercise will not guarantee ... //Economist John Cawley of Cornell University and colleagues found in ... students taking part in physical education decreased from 42% in ... data on 37,000 teens in grades nine through 12. All ...
... highly sensitive to allergies in the first three years of ... ,Sabina Illi and colleagues at the University Children's Hospital, Munich, ... allergens in early life and the effect of the sensitization ... They had reported their findings in the latest issue of ...
... with their doctors and practice nurses every year, according to ... revealed that over 11 million appointments with the doctors were ... in UK last year. The problem is more prevalent in ... Midlands are just behind. The survey was conducted among 329 ...
... that a specific variety of adult stem ... or other// types of tissue depending on the response ... researchers found that mesenchymal stem cells, which are commonly ... from their local environment, allowing a transformation into different ...
Cached Medicine News:Health News:Babies Prone To Allergies More likely To Be Asthmatic 2Health News:Adult stem cells are sensitive to responses from the environment 2
With BareWire technology, the wire crosses the lesion first, independent of the filter and delivery catheter. All other actions, including filter placement and retrieval, balloon dilatations, and ste...
... been uniquely designed to fit the ... integrated networks spanning multi-facilities. From test ... and accounts receivable, Centricity Ultra facilitates ... All system modules are fully integrated ...
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... Dehydroepiandrosterone sulfate (DHEA-S) is the sulfate ester ... by enzymatic conversion of DHEA in adrenal ... C19 steroid secreted by the adrenal cortex, ... estrogen biosynthesis. DHEA possesses relatively weak androgenic ...
Medicine Products: